NCT01420770View on ClinicalTrials.gov

Phase 2 Study of SAR302503 in Patients With Myelofibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Hematopoietic Neoplasm
Interventions
DRUG

SAR302503

"Pharmaceutical form:capsule~Route of administration: oral"

Trial Locations (4)

44718

Investigational Site Number 840007, Canton

55905

Investigational Site Number 840006, Rochester

94143

Investigational Site Number 840001, San Francisco

48109-0759

Investigational Site Number 840003, Ann Arbor

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01420770 - Phase 2 Study of SAR302503 in Patients With Myelofibrosis | Biotech Hunter | Biotech Hunter